Characterisation of Staphylococci species from neonatal blood cultures in low- and middle-income countries.
Early onset
Epidemiology
Genomics
LMIC
Late onset
Mammaliicocci
Mortality
Neonatal sepsis
Staphylococci
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
01 Jul 2022
01 Jul 2022
Historique:
received:
09
05
2022
accepted:
15
06
2022
entrez:
5
7
2022
pubmed:
6
7
2022
medline:
8
7
2022
Statut:
epublish
Résumé
In low- and middle-income countries (LMIC) Staphylococcus aureus is regarded as one of the leading bacterial causes of neonatal sepsis, however there is limited knowledge on the species diversity and antimicrobial resistance caused by Gram-positive bacteria (GPB). We characterised GPB isolates from neonatal blood cultures from LMICs in Africa (Ethiopia, Nigeria, Rwanda, and South Africa) and South-Asia (Bangladesh and Pakistan) between 2015-2017. We determined minimum inhibitory concentrations and performed whole genome sequencing (WGS) on Staphylococci isolates recovered and clinical data collected related to the onset of sepsis and the outcome of the neonate up to 60 days of age. From the isolates recovered from blood cultures, Staphylococci species were most frequently identified. Out of 100 S. aureus isolates sequenced, 18 different sequence types (ST) were found which unveiled two small epidemiological clusters caused by methicillin resistant S. aureus (MRSA) in Pakistan (ST8) and South Africa (ST5), both with high mortality (n = 6/17). One-third of S. aureus was MRSA, with methicillin resistance also detected in Staphylococcus epidermidis, Staphylococcus haemolyticus and Mammaliicoccus sciuri. Through additional WGS analysis we report a cluster of M. sciuri in Pakistan identified between July-November 2017. In total we identified 14 different GPB bacterial species, however Staphylococci was dominant. These findings highlight the need of a prospective genomic epidemiology study to comprehensively assess the true burden of GPB neonatal sepsis focusing specifically on mechanisms of resistance and virulence across species and in relation to neonatal outcome.
Sections du résumé
BACKGROUND
BACKGROUND
In low- and middle-income countries (LMIC) Staphylococcus aureus is regarded as one of the leading bacterial causes of neonatal sepsis, however there is limited knowledge on the species diversity and antimicrobial resistance caused by Gram-positive bacteria (GPB).
METHODS
METHODS
We characterised GPB isolates from neonatal blood cultures from LMICs in Africa (Ethiopia, Nigeria, Rwanda, and South Africa) and South-Asia (Bangladesh and Pakistan) between 2015-2017. We determined minimum inhibitory concentrations and performed whole genome sequencing (WGS) on Staphylococci isolates recovered and clinical data collected related to the onset of sepsis and the outcome of the neonate up to 60 days of age.
RESULTS
RESULTS
From the isolates recovered from blood cultures, Staphylococci species were most frequently identified. Out of 100 S. aureus isolates sequenced, 18 different sequence types (ST) were found which unveiled two small epidemiological clusters caused by methicillin resistant S. aureus (MRSA) in Pakistan (ST8) and South Africa (ST5), both with high mortality (n = 6/17). One-third of S. aureus was MRSA, with methicillin resistance also detected in Staphylococcus epidermidis, Staphylococcus haemolyticus and Mammaliicoccus sciuri. Through additional WGS analysis we report a cluster of M. sciuri in Pakistan identified between July-November 2017.
CONCLUSIONS
CONCLUSIONS
In total we identified 14 different GPB bacterial species, however Staphylococci was dominant. These findings highlight the need of a prospective genomic epidemiology study to comprehensively assess the true burden of GPB neonatal sepsis focusing specifically on mechanisms of resistance and virulence across species and in relation to neonatal outcome.
Identifiants
pubmed: 35790903
doi: 10.1186/s12879-022-07541-w
pii: 10.1186/s12879-022-07541-w
pmc: PMC9254428
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
593Subventions
Organisme : Bill and Melinda Gates Foundation
ID : OPP1119772
Informations de copyright
© 2022. The Author(s).
Références
PLoS Pathog. 2014 Feb 13;10(2):e1003871
pubmed: 24550724
Antimicrob Agents Chemother. 2009 Dec;53(12):4961-7
pubmed: 19721075
Early Hum Dev. 2012 May;88 Suppl 2:S69-74
pubmed: 22633519
Bioinformatics. 2015 Nov 15;31(22):3691-3
pubmed: 26198102
Bioinformatics. 2016 Jan 15;32(2):292-4
pubmed: 26428292
Lancet Infect Dis. 2021 Dec;21(12):1677-1688
pubmed: 34384533
J Antimicrob Chemother. 2020 Dec 1;75(12):3491-3500
pubmed: 32780112
J Clin Microbiol. 2014 Dec;52(12):4305-8
pubmed: 25297335
Nucleic Acids Res. 2016 Jan 4;44(D1):D694-7
pubmed: 26578559
mBio. 2016 May 05;7(3):
pubmed: 27150362
Paediatr Int Child Health. 2015 Aug;35(3):265-72
pubmed: 25940506
Arch Dis Child. 2021 Jan 22;:
pubmed: 33483376
Microb Drug Resist. 2020 Aug;26(8):951-970
pubmed: 32043916
Nucleic Acids Res. 2016 Jul 8;44(W1):W242-5
pubmed: 27095192
Pediatr Infect Dis J. 2008 Oct;27(10):925-6
pubmed: 18820590
Lancet. 2017 Sep 16;390(10100):1151-1210
pubmed: 28919116
Int J Syst Evol Microbiol. 2020 Nov;70(11):5926-5936
pubmed: 33052802
Microb Drug Resist. 2013 Feb;19(1):48-56
pubmed: 23083127
Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):E10596-E10604
pubmed: 29158405
Clin Microbiol Infect. 2006 Dec;12(12):1230-3
pubmed: 17121632
Pediatr Infect Dis J. 2015 Jan;34(1):e1-8
pubmed: 25389919
BMJ. 2019 Jan 22;364:k5314
pubmed: 30670451
Microb Genom. 2016 Apr 29;2(4):e000056
pubmed: 28348851
PLoS One. 2016 Jun 21;11(6):e0157718
pubmed: 27327771
Infect Immun. 2004 Feb;72(2):1210-5
pubmed: 14742578
J Antimicrob Chemother. 2021 Jan 1;76(1):101-109
pubmed: 33009809
Pediatr Int. 2014 Feb;56(1):60-6
pubmed: 24003995
Lancet Infect Dis. 2019 Nov;19(11):1219-1234
pubmed: 31522858
J Infect Dev Ctries. 2016 Dec 30;10(12):1338-1344
pubmed: 28036314
Zoonoses Public Health. 2020 Feb;67(1):93-95
pubmed: 31769606
Pathogens. 2021 Dec 10;10(12):
pubmed: 34959562
J Antimicrob Chemother. 2014 Nov;69(11):2920-7
pubmed: 25038069
PLoS Comput Biol. 2017 Jun 8;13(6):e1005595
pubmed: 28594827
Nat Commun. 2018 Nov 28;9(1):5034
pubmed: 30487573
Clin Microbiol Infect. 2011 May;17(5):785-92
pubmed: 20854426
Bioinformatics. 2019 Nov 1;35(21):4453-4455
pubmed: 31070718
Lancet Glob Health. 2016 Oct;4(10):e752-60
pubmed: 27633433
Braz J Med Biol Res. 2012 Jul;45(7):637-43
pubmed: 22527128
Pediatr Infect Dis J. 2022 Mar 1;41(3S):S26-S35
pubmed: 35134037
Front Microbiol. 2018 Aug 22;9:1901
pubmed: 30186248
PLoS One. 2018 Jul 17;13(7):e0200350
pubmed: 30016358
J Trop Pediatr. 2015 Feb;61(1):1-13
pubmed: 25604489
Mol Biol Evol. 2020 May 1;37(5):1530-1534
pubmed: 32011700
PLoS One. 2020 Aug 10;15(8):e0237085
pubmed: 32776958
Arch Iran Med. 2016 Dec;19(12):866-869
pubmed: 27998162
Pediatr Infect Dis J. 2016 May;35(5 Suppl 1):S52-4
pubmed: 27070065
Expert Rev Anti Infect Ther. 2020 May;18(5):443-452
pubmed: 32070161
J Infect Dev Ctries. 2011 Nov 15;5(11):799-803
pubmed: 22112734
PLoS One. 2010 Mar 10;5(3):e9490
pubmed: 20224823
EClinicalMedicine. 2022 Jan 10;44:101259
pubmed: 35059614
Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W20-5
pubmed: 15215342
Vet Microbiol. 2014 Jul 16;171(3-4):342-56
pubmed: 24629775
Genome Biol. 2016 Jun 20;17(1):132
pubmed: 27323842
PLoS One. 2013 Apr 25;8(4):e62020
pubmed: 23637953
Nat Microbiol. 2017 Oct;2(10):1381-1388
pubmed: 28785103
Wellcome Open Res. 2018 Sep 24;3:124
pubmed: 30345391
Nat Microbiol. 2021 Apr;6(4):512-523
pubmed: 33782558
Bioinformatics. 2014 Jul 15;30(14):2068-9
pubmed: 24642063
J Microbiol Methods. 2018 Jun;149:106-119
pubmed: 29730327
J Med Microbiol. 2013 Dec;62(Pt 12):1852-1863
pubmed: 23946478
Nucleic Acids Res. 2015 Feb 18;43(3):e15
pubmed: 25414349
Pediatrics. 2004 Oct;114(4):953-61
pubmed: 15466090
Scand J Infect Dis. 2001;33(12):930-2
pubmed: 11868769
J Matern Fetal Neonatal Med. 2016 Dec;29(24):3993-8
pubmed: 26858036
Mikrobiyol Bul. 2006 Oct;40(4):397-400
pubmed: 17205699